{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T09:06:46Z","timestamp":1793869606318,"version":"4.6.1"},"reference-count":222,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2015,5,26]],"date-time":"2015-05-26T00:00:00Z","timestamp":1432598400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1038\/nrclinonc.2015.92","type":"journal-article","created":{"date-parts":[[2015,5,26]],"date-time":"2015-05-26T14:22:41Z","timestamp":1432650161000},"page":"465-480","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":117,"title":["Adolescent and young adult patients with cancer: a milieu of unique features"],"prefix":"10.1038","volume":"12","author":[{"given":"Leonard","family":"Sender","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keri B.","family":"Zabokrtsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,26]]},"reference":[{"key":"BFnrclinonc201592_CR1","unstructured":"Adolescent and Young Adult Oncology Progress Review Group. Closing the gap: research and care imperatives for adolescents and young adults with cancer. Office of Science Planning & Assessment (OSPA) Library [online] , (2006)."},{"key":"BFnrclinonc201592_CR2","volume-title":"Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975\u20132000","author":"A Bleyer","year":"2006","unstructured":"Bleyer, A., O'Leary, M., Barr, R. & Ries, L. A. G. (eds) Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975\u20132000 (National Cancer Institute 2006)."},{"key":"BFnrclinonc201592_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1089\/jayao.2011.1500","volume":"1","author":"A Bleyer","year":"2011","unstructured":"Bleyer, A., Albritton, K. H., Barr, R. D., Lewis, I. J. & Sender, L. S. Trailblazers in adolescent and young adult oncology. J. Adolesc. Young Adult Oncol. 1, 13\u201318 (2011).","journal-title":"J. Adolesc. Young Adult Oncol."},{"key":"BFnrclinonc201592_CR4","unstructured":"Australian Institute of Health and Welfare. Cancer in adolescents and young adults in Australia. Australian Institute of Health and Welfare [online] , (2011)."},{"key":"BFnrclinonc201592_CR5","doi-asserted-by":"publisher","first-page":"E187","DOI":"10.1503\/CMAJ.100800","volume":"183","author":"P De","year":"2011","unstructured":"De, P. et al. Candian adolescents and young adults with cancer: opportunity to improve coordination and level of care. CMAJ 183, E187\u2013E194 (2011).","journal-title":"CMAJ"},{"key":"BFnrclinonc201592_CR6","doi-asserted-by":"publisher","first-page":"e42607","DOI":"10.1371\/journal.pone.0042607","volume":"7","author":"QJ Wu","year":"2012","unstructured":"Wu, Q. J. et al. Cancer incidence among adolescents and young adults in urban Shanghai, 1973\u20132005. PLoS ONE 7, e42607 (2012).","journal-title":"PLoS ONE"},{"key":"BFnrclinonc201592_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1089\/jayao.2010.0007","volume":"1","author":"S Rajani","year":"2011","unstructured":"Rajani, S., Young, A. J., McGoldrick, D. A., Pearce, D. L. & Sharaf, S. M. The International Charter of Rights for Young People with Cancer. J. Adolesc. Young Adult Oncol. 1, 49\u201352 (2011).","journal-title":"J. Adolesc. Young Adult Oncol."},{"key":"BFnrclinonc201592_CR8","unstructured":"Howlander, N. et al. SEER Cancer Statistics Review (CSR) 1975\u20132011. Surveillance, Epidemiology, and End Results Program [online] , (2014)."},{"key":"BFnrclinonc201592_CR9","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/nrc2349","volume":"8","author":"A Bleyer","year":"2008","unstructured":"Bleyer, A. et al. The distinctive biology of cancer in adolescents and young adults. Nat. Rev. Cancer 8, 288\u2013298 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnrclinonc201592_CR10","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/PPO.0b013e31826b1232","volume":"18","author":"CA Portell","year":"2012","unstructured":"Portell, C. A. & Sweetenham, J. W. Adult lymphoblastic lymphoma. Cancer J. 18, 432\u2013438 (2012).","journal-title":"Cancer J."},{"key":"BFnrclinonc201592_CR11","doi-asserted-by":"publisher","first-page":"288","DOI":"10.6004\/jnccn.2010.0021","volume":"8","author":"AD Zelenetz","year":"2010","unstructured":"Zelenetz, A. D. et al. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J. Natl Compr. Canc. Netw. 8, 288\u2013334 (2010).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"BFnrclinonc201592_CR12","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1093\/annonc\/mdu153","volume":"25","author":"M Wilhelm","year":"2014","unstructured":"Wilhelm, M. et al. ENCCA WP17-WP7 consensus paper on teenagers and young adults (TYA) with bone sarcomas. Ann. Oncol. 25, 1500\u20131505 (2014).","journal-title":"Ann. Oncol."},{"key":"BFnrclinonc201592_CR13","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1186\/bcr3556","volume":"15","author":"TH Keegan","year":"2013","unstructured":"Keegan, T. H. et al. Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women. Breast Cancer Res. 15, R95 (2013).","journal-title":"Breast Cancer Res."},{"key":"BFnrclinonc201592_CR14","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/jnci\/djr094","volume":"103","author":"JV Tricoli","year":"2011","unstructured":"Tricoli, J. V., Seibel, N. L., Blair, D. G., Albritton, K. & Hayes-Lattin, B. Unique characteristics of adolescent and young adult acute lymphoblastic leukemia, breast cancer, and colon cancer. J. Natl Cancer Inst. 103, 628\u2013635 (2011).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc201592_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3322\/caac.21208","volume":"64","author":"R Siegel","year":"2014","unstructured":"Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics, 2014. CA Cancer J. Clin. 64, 9\u201329 (2014).","journal-title":"CA Cancer J. Clin."},{"key":"BFnrclinonc201592_CR16","first-page":"1","volume":"62","author":"M Heron","year":"2013","unstructured":"Heron, M. Deaths: leading causes for 2010. Natl Vital Stat. Rep. 62, 1\u201396 (2013).","journal-title":"Natl Vital Stat. Rep."},{"key":"BFnrclinonc201592_CR17","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJM194806032382301","volume":"238","author":"S Farber","year":"1948","unstructured":"Farber, S. & Diamond, L. K. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N. Engl. J. Med. 238, 787\u2013793 (1948).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201592_CR18","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","volume":"30","author":"SP Hunger","year":"2012","unstructured":"Hunger, S. P. et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children's Oncology Group. J. Clin. Oncol. 30, 1663\u20131669 (2012).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201592_CR19","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1200\/JCO.2010.32.0325","volume":"29","author":"CH Pui","year":"2011","unstructured":"Pui, C. H. et al. Improved prognosis for older adolescents with acute lymphoblastic leukemia. J. Clin. Oncol. 29, 386\u2013391 (2011).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201592_CR20","first-page":"2009","volume":"96","author":"W Stock","year":"2000","unstructured":"Stock, W. et al. Outcome of adolescents and young adults with acute lymphoblastic leukemia (ALL): a comparison of Children's Cancer Group (CCG) and Cancer and Leukemia Group B (CALGB) regimens [abstract]. Blood 96, 2009 (2000).","journal-title":"Blood"},{"key":"BFnrclinonc201592_CR21","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1200\/JCO.2003.02.053","volume":"21","author":"N Boissel","year":"2003","unstructured":"Boissel, N. et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J. Clin. Oncol. 21, 774\u2013780 (2003).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201592_CR22","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/sj.leu.2403538","volume":"18","author":"JM de Bont","year":"2004","unstructured":"de Bont, J. M. et al. Significant differences in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs. adult protocols in the Netherlands. Leukemia 18, 2032\u20132035 (2004).","journal-title":"Leukemia"},{"key":"BFnrclinonc201592_CR23","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/pbc.20749","volume":"48","author":"R Ramanujachar","year":"2007","unstructured":"Ramanujachar, R. et al. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLX11\/E2993) trials. Pediatr. Blood Cancer 48, 254\u2013261 (2007).","journal-title":"Pediatr. Blood Cancer"},{"key":"BFnrclinonc201592_CR24","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1182\/blood-2008-01-130237","volume":"112","author":"W Stock","year":"2008","unstructured":"Stock, W. et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Leukemia Group B studies. Blood 112, 1646\u20131654 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc201592_CR25","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.6004\/jnccn.2012.0117","volume":"10","author":"PF Coccia","year":"2012","unstructured":"Coccia, P. F. et al. Adolescent and young adult oncology. Clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 10, 1112\u20131150 (2012).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"BFnrclinonc201592_CR26","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1007\/s00520-013-1809-4","volume":"21","author":"AA Gupta","year":"2013","unstructured":"Gupta, A. A., Edelstein, K., Albert-Green, A. & D'Agostino, N. Assessing information and service needs of young adults with cancer at a single institution. The importance of information on cancer diagnosis, fertility preservation, diet, and exercise. Support. Care Cancer 21, 2477\u20132484 (2013).","journal-title":"Support. Care Cancer"},{"key":"BFnrclinonc201592_CR27","doi-asserted-by":"publisher","first-page":"150","DOI":"10.5172\/conu.2014.46.2.150","volume":"46","author":"JA Barling","year":"2014","unstructured":"Barling, J. A., Stevens, J. A. & Davies, K. M. The reality of hospitalisation: stories from family members of their hospital experience for adolescents and young adults living with and dying from cancer. Contemp. Nurse 46, 150\u2013160 (2014).","journal-title":"Contemp. Nurse"},{"key":"BFnrclinonc201592_CR28","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1200\/JCO.2003.11.116","volume":"21","author":"CA Schiffer","year":"2003","unstructured":"Schiffer, C. A. Differences in outcomes in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both? J. Clin. Oncol. 21, 760\u2013761 (2003).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201592_CR29","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online] , (2013)."},{"key":"BFnrclinonc201592_CR30","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1182\/blood.V122.21.3903.3903","volume":"122","author":"AS Advani","year":"2013","unstructured":"Advani, A. S. et al. Frontline-treatment of acute lymphoblastic leukemia (ALL) in older adolescents and young adults (AYA) using a pediatric regimen is feasible: toxicity results of the prospective US Intergroup Trial C10403 (Alliance) [abstract]. Blood 122, 3903 (2013).","journal-title":"Blood"},{"key":"BFnrclinonc201592_CR31","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online] , (2013)."},{"key":"BFnrclinonc201592_CR32","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/ng.763","volume":"43","author":"JJ Yang","year":"2011","unstructured":"Yang, J. J. et al. Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat. Genet. 43, 237\u2013241 (2011).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201592_CR33","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1200\/JCO.2011.38.0345","volume":"30","author":"H Xu","year":"2012","unstructured":"Xu, H. et al. ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. J. Clin. Oncol. 30, 751\u2013757 (2012).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201592_CR34","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1093\/jnci\/djt042","volume":"105","author":"H Xu","year":"2013","unstructured":"Xu, H. et al. Novel susceptibility variants at 10p12.31\u2013122 for childhood acute lymphoblastic leukemia in ethnically diverse populations. J. Natl Cancer Inst. 105, 733\u2013742 (2013).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc201592_CR35","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.1182\/blood-2013-01-480335","volume":"121","author":"S Radtke","year":"2013","unstructured":"Radtke, S. et al. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood 121, 5145\u20135153 (2013).","journal-title":"Blood"},{"key":"BFnrclinonc201592_CR36","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/clpt.2008.191","volume":"84","author":"BG Kapogiannis","year":"2008","unstructured":"Kapogiannis, B. G. & Mattison, D. R. Adolescents in clinical trials. Clin. Pharmacol. Ther. 84, 655\u2013659 (2008).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BFnrclinonc201592_CR37","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1172\/JCI31771","volume":"117","author":"PC Nowell","year":"2007","unstructured":"Nowell, P. C. Discovery of the Philadelphia chromosome: a personal perspective. J. Clin. Invest. 117, 2033\u20132035 (2007).","journal-title":"J. Clin. Invest."},{"key":"BFnrclinonc201592_CR38","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/300765a0","volume":"300","author":"A de Klein","year":"1982","unstructured":"de Klein, A. et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 300, 765\u2013767 (1982).","journal-title":"Nature"},{"key":"BFnrclinonc201592_CR39","doi-asserted-by":"publisher","first-page":"5175","DOI":"10.1200\/JCO.2008.21.2514","volume":"27","author":"KR Schultz","year":"2009","unstructured":"Schultz, K. R. et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children's Oncology Group study. J. Clin. Oncol. 27, 5175\u20135181 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201592_CR40","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1182\/asheducation-2011.1.361","volume":"2011","author":"SP Hunger","year":"2011","unstructured":"Hunger, S. P. Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia. Hematology Am. Soc. Hematol. Educ. Program 2011, 361\u2013365 (2011).","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"BFnrclinonc201592_CR41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1182\/blood.V56.1.15.15","volume":"56","author":"JR Priest","year":"1980","unstructured":"Priest, J. R. et al. Philadelphia chromosome positive childhood acute lymphoblastic leukemia. Blood 56, 15\u201322 (1980).","journal-title":"Blood"},{"key":"BFnrclinonc201592_CR42","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3109\/10428190009148847","volume":"36","author":"S Faderl","year":"2000","unstructured":"Faderl, S. et al. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk. Lymphoma 36, 263\u2013273 (2000).","journal-title":"Leuk. Lymphoma"},{"key":"BFnrclinonc201592_CR43","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1365-2141.2008.07417.x","volume":"144","author":"CJ Harrison","year":"2009","unstructured":"Harrison, C. J. Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br. J. Haematol. 144, 147\u2013156 (2009).","journal-title":"Br. J. Haematol."},{"key":"BFnrclinonc201592_CR44","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3345\/kjp.2011.54.3.106","volume":"54","author":"HH Koo","year":"2011","unstructured":"Koo, H. H. Philadelphia chromosome-positive acute lymphoblastic leukemia in childhood. Korean J. Pediatr. 54, 106\u2013110 (2011).","journal-title":"Korean J. Pediatr."},{"key":"BFnrclinonc201592_CR45","doi-asserted-by":"publisher","first-page":"5175","DOI":"10.1200\/JCO.2008.21.2514","volume":"27","author":"KR Schultz","year":"2009","unstructured":"Schultz, K. R. et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children's Oncology Group study. J. Clin. Oncol. 27, 5175\u20135181 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201592_CR46","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/leu.2014.30","volume":"28","author":"KR Schultz","year":"2014","unstructured":"Schultz, K. R. et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. Leukemia 28, 1467\u20131471 (2014).","journal-title":"Leukemia"},{"key":"BFnrclinonc201592_CR47","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/cncr.25690","volume":"117","author":"HJ Lee","year":"2011","unstructured":"Lee, H. J., Thompson, J. E., Wang, E. S. & Wetzler, M. Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives. Cancer 117, 1583\u20131594 (2011).","journal-title":"Cancer"},{"key":"BFnrclinonc201592_CR48","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1634\/theoncologist.2006-0017","volume":"13","author":"MH Cohen","year":"2008","unstructured":"Cohen, M. H., Johnson, J. R., Justice, R. & Pazdur, R. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia\/lymphoma. Oncologist 13, 709\u2013714 (2008).","journal-title":"Oncologist"},{"key":"BFnrclinonc201592_CR49","doi-asserted-by":"publisher","unstructured":"Winter, S. S. et al. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatr. Blood Cancer. http:\/\/dx.doi.org\/10.1002\/pbc.25470 .","DOI":"10.1002\/pbc.25470"},{"key":"BFnrclinonc201592_CR50","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1172\/JCI61269","volume":"122","author":"P Van Vlierberghe","year":"2012","unstructured":"Van Vlierberghe, P. & Ferrando, A. The molecular basis of T cell acute lymphoblastic leukemia. J. Clin. Invest. 122, 3398\u20133406 (2012).","journal-title":"J. Clin. Invest."},{"key":"BFnrclinonc201592_CR51","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1200\/JCO.2011.40.3907","volume":"30","author":"AV Moorman","year":"2012","unstructured":"Moorman, A. V. et al. IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia. J. Clin. Oncol. 30, 3100\u20133108 (2012).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201592_CR52","doi-asserted-by":"publisher","first-page":"5312","DOI":"10.1182\/blood-2009-09-245944","volume":"115","author":"RC Harvey","year":"2010","unstructured":"Harvey, R. C. et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic\/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 115, 5312\u20135321 (2010).","journal-title":"Blood"},{"key":"BFnrclinonc201592_CR53","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/978-1-60761-707-5_5","volume-title":"Adult acute lymphoblastic leukemia: biology and treatment","author":"AV Moorman","year":"2011","unstructured":"Moorman, A. V. & Harrison, C. J. in Adult acute lymphoblastic leukemia: biology and treatment. (eds Advani, A. S. & Lazarus, H. M.) 61\u201376 (Springer Science+Business Media, 2011)."},{"key":"BFnrclinonc201592_CR54","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1182\/asheducation-2013.1.118","volume":"2013","author":"CJ Harrison","year":"2013","unstructured":"Harrison, C. J. Targeting signaling pathways in acute lymphoblastic leukemia: new insights. Hematology Am. Soc. Hematol. Educ. Program 2013, 118\u2013125 (2013).","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"BFnrclinonc201592_CR55","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/EdBook_AM.2013.33.285","volume":"2013","author":"AS Advani","year":"2013","unstructured":"Advani, A. S. Biology and treatment of acute lymphocytic leukemia in adolescents and young adults. Am. Soc. Clin. Oncol. Educ. Book 2013, 285\u2013289 (2013).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"BFnrclinonc201592_CR56","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1056\/NEJMoa0808253","volume":"360","author":"CG Mullighan","year":"2009","unstructured":"Mullighan, C. G. et al. Deletion of IKZF1 and prognosis in acute lymphblastic leukemia. N. Engl. J. Med. 360, 470\u2013480 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201592_CR57","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1182\/blood-2009-05-218560","volume":"115","author":"H Kang","year":"2010","unstructured":"Kang, H. et al. Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood 115, 1394\u20131405 (2010).","journal-title":"Blood"},{"key":"BFnrclinonc201592_CR58","doi-asserted-by":"publisher","first-page":"4874","DOI":"10.1182\/blood-2009-08-239681","volume":"116","author":"RC Harvey","year":"2010","unstructured":"Harvey, R. C. et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 116, 4874\u20134884 (2010).","journal-title":"Blood"},{"key":"BFnrclinonc201592_CR59","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1200\/JCO.2014.55.4105","volume":"32","author":"KG Roberts","year":"2014","unstructured":"Roberts, K. G. et al. Outcomes of children with BCR\u2013ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J. Clin. Oncol. 32, 3012\u20133020 (2014).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201592_CR60","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","volume":"360","author":"CH Pui","year":"2009","unstructured":"Pui, C. H. et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N. Engl. J. Med. 360, 2730\u20132741 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201592_CR61","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1470-2045(15)70082-3","volume":"16","author":"CH Pui","year":"2015","unstructured":"Pui, C. H. et al. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncol. 16, 465\u2013474 (2015).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc201592_CR62","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","volume":"371","author":"KG Roberts","year":"2014","unstructured":"Roberts, K. G. et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N. Engl. J. Med. 371, 1005\u20131015 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201592_CR63","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/107327481302000108","volume":"20","author":"JB Brayer","year":"2013","unstructured":"Brayer, J. B. & Pinilla-Ibarz, J. Developing strategies in the immunotherapy of leukemias. Cancer Control 20, 49\u201359 (2013).","journal-title":"Cancer Control"},{"key":"BFnrclinonc201592_CR64","unstructured":"CAR T-Cell therapy: engineering patients' immune cells to treat their cancers. The National Cancer Institute at the National Institute of Health [online] , (2014)."},{"key":"BFnrclinonc201592_CR65","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp, S. A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509\u20131518 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201592_CR66","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s12185-013-1479-5","volume":"99","author":"ML Davila","year":"2014","unstructured":"Davila, M. L. et al. Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int. J. Hematol. 99, 361\u2013371 (2014).","journal-title":"Int. J. Hematol."},{"key":"BFnrclinonc201592_CR67","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/imr.12131","volume":"257","author":"G Dotti","year":"2014","unstructured":"Dotti, G., Gottschalk, S., Savoldo, B. & Brenner, M. K. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol. Rev. 257, 107\u2013126 (2014).","journal-title":"Immunol. Rev."},{"key":"BFnrclinonc201592_CR68","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1182\/asheducation-2013.1.348","volume":"2013","author":"TJ Fry","year":"2013","unstructured":"Fry, T. J. & Mackall, C. L. T-cell adoptive immunotherapy for acute lymphoblastic leukemia. Hematology Am. Soc. Hematol. Educ. Program 2013, 348\u2013353 (2013).","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"BFnrclinonc201592_CR69","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/PPO.0000000000000031","volume":"20","author":"CA Ramos","year":"2014","unstructured":"Ramos, C. A., Savoldo, B. & Dotti, G. CD19-CAR trials. Cancer J. 20, 112\u2013118 (2014).","journal-title":"Cancer J."},{"key":"BFnrclinonc201592_CR70","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3109\/10428194.2012.715350","volume":"54","author":"XJ Xu","year":"2013","unstructured":"Xu, X. J., Zhao, H. Z. & Tang, Y. M. Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials. Leuk. Lymphoma 54, 255\u2013260 (2013).","journal-title":"Leuk. Lymphoma"},{"key":"BFnrclinonc201592_CR71","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila, M. L. et al. Efficacy and toxicity management of 19\u201328z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25 (2014).","journal-title":"Sci. Transl. Med."},{"key":"BFnrclinonc201592_CR72","doi-asserted-by":"publisher","first-page":"177-ra38","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens, R. J. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177-ra38 (2013).","journal-title":"Sci. Transl. Med."},{"key":"BFnrclinonc201592_CR73","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","volume":"122","author":"JN Kochenderfer","year":"2013","unstructured":"Kochenderfer, J. N. et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122, 4129\u20134139 (2013).","journal-title":"Blood"},{"key":"BFnrclinonc201592_CR74","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","volume":"122","author":"CR Cruz","year":"2013","unstructured":"Cruz, C. R. et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 122, 2965\u20132973 (2013).","journal-title":"Blood"},{"key":"BFnrclinonc201592_CR75","unstructured":"Novartis Media Releases. Novartis personalized cell therapy CTL019 receives FDA Breakthrough Therapy designation [online] , (2014)."},{"key":"BFnrclinonc201592_CR76","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1080\/10428190902943077","volume":"50","author":"D Nagorsen","year":"2009","unstructured":"Nagorsen, D. et al. Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leuk. Lymphoma 50, 886\u2013891 (2009).","journal-title":"Leuk. Lymphoma"},{"key":"BFnrclinonc201592_CR77","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1038\/sj.leu.2404866","volume":"21","author":"JF Dijoseph","year":"2007","unstructured":"Dijoseph, J. F., Dougher, M. M., Armellino, D. C., Evans, D. Y. & Damle, N. K. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia 21, 2240\u20132245 (2007).","journal-title":"Leukemia"},{"key":"BFnrclinonc201592_CR78","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/leu.2010.239","volume":"25","author":"R Handgretinger","year":"2011","unstructured":"Handgretinger, R. et al. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia 25, 181\u2013184 (2011).","journal-title":"Leukemia"},{"key":"BFnrclinonc201592_CR79","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","volume":"29","author":"MS Topp","year":"2011","unstructured":"Topp, M. S. et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J. Clin. Oncol. 29, 2493\u20132498 (2011).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201592_CR80","unstructured":"Amgen News Releases. Amgen receives FDA Breakthrough Therapy designation for investigational BiTE\u00ae antibody blinatumomab in acute lymphoblastic leukemia [online] , (2014)."},{"key":"BFnrclinonc201592_CR81","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11899-014-0202-9","volume":"9","author":"ST Kochuparambil","year":"2014","unstructured":"Kochuparambil, S. T. & Litzow, M. R. Novel antibody therapy in acute lymphoblastic leukemia. Curr. Hematol. Malig. Rep. 9, 165\u2013173 (2014).","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"BFnrclinonc201592_CR82","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/pbc.24721","volume":"61","author":"M Rytting","year":"2014","unstructured":"Rytting, M., Triche, L., Thomas, D., O'Brien, S. & Kantarjian, H. Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia. Pediatr. Blood Cancer 61, 369\u2013372 (2014).","journal-title":"Pediatr. Blood Cancer"},{"key":"BFnrclinonc201592_CR83","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1001\/archdermatol.2011.44","volume":"147","author":"AK Hausauer","year":"2011","unstructured":"Hausauer, A. K., Swetter, S. M., Cockburn, M. G. & Clarke, C. A. Increases in melanoma among adolescent girls and young women in California: trends by socioeconomic status and UV radiation exposure. Arch. Dermatol. 147, 783\u2013789 (2011).","journal-title":"Arch. Dermatol."},{"key":"BFnrclinonc201592_CR84","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.sder.2010.10.005","volume":"29","author":"DS Rigel","year":"2010","unstructured":"Rigel, D. S. Epidemology of melanoma. Semin. Cutan. Med. Surg. 29, 204\u2013209 (2010).","journal-title":"Semin. Cutan. Med. Surg."},{"key":"BFnrclinonc201592_CR85","unstructured":"Tavernise, S. Surgeon General calls for action to reduce skin cancer rate. The New York Times [online] , (2014)."},{"key":"BFnrclinonc201592_CR86","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/pcmr.12035","volume":"26","author":"F Liu","year":"2013","unstructured":"Liu, F. et al. A unique gender difference in early onset melanoma implies that in addition to ultraviolet light exposure other causative factors are important. Pigment Cell Melanoma Res. 26, 128\u2013135 (2013).","journal-title":"Pigment Cell Melanoma Res."},{"key":"BFnrclinonc201592_CR87","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/CCO.0b013e3283252fc5","volume":"21","author":"JM Schulman","year":"2009","unstructured":"Schulman, J. M. & Fisher, D. E. Indoor ultraviolet tanning and skin cancer: health risks and opportunities. Curr. Opin. Oncol. 21, 144\u2013149 (2009).","journal-title":"Curr. Opin. Oncol."},{"key":"BFnrclinonc201592_CR88","unstructured":"Skin Cancer Foundation. Facts about sunburn and skin cancer [online] , (2014)."},{"key":"BFnrclinonc201592_CR89","doi-asserted-by":"publisher","first-page":"e4757","DOI":"10.1136\/bmj.e4757","volume":"345","author":"M Boniol","year":"2012","unstructured":"Boniol, M., Autier, P., Boyle, P. & Gandini, S. Cutaneous melanoma attributable to sunbed use: systematic review and meta-analyis. BMJ 345, e4757 (2012).","journal-title":"BMJ"},{"key":"BFnrclinonc201592_CR90","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1158\/1055-9965.EPI-09-1249","volume":"19","author":"D Lazovich","year":"2010","unstructured":"Lazovich, D. et al. Indoor tanning and risk of melanoma: a case\u2013control study in a highly exposed population. Cancer Epidemiol. Biomarkers Prev. 19, 1557\u20131568 (2010).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"BFnrclinonc201592_CR91","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1200\/JCO.2010.28.7078","volume":"29","author":"AC Green","year":"2011","unstructured":"Green, A. C., Williams, G. M., Logan, V. & Strutton, G. M. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J. Clin. Oncol. 29, 257\u2013263 (2011).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201592_CR92","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1111\/j.0022-202X.2004.23466.x","volume":"123","author":"E Thieden","year":"2004","unstructured":"Thieden, E., Philipsen, P. A., Sandby-M\u00f8ller, J., Heydenreich, J. & Wulf, H. C. Proportion of lifetime UV dose received by children, teenagers and adults based on time-stamped personal dosimetry. J. Invest. Dermatol. 123, 1147\u20131150 (2004).","journal-title":"J. Invest. Dermatol."},{"key":"BFnrclinonc201592_CR93","unstructured":"American Cancer Society. Known and probable human carcinogens [online] , (2014)."},{"key":"BFnrclinonc201592_CR94","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.det.2014.03.011","volume":"32","author":"SE Mancebo","year":"2014","unstructured":"Mancebo, S. E., Hu, J. Y. & Wang, S. Q. Sunscreens: a review of health benefits, regulations, and controversies. Dermatol. Clin. 32, 427\u2013438 (2014).","journal-title":"Dermatol. Clin."},{"key":"BFnrclinonc201592_CR95","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/her\/cyq066","volume":"26","author":"S Potente","year":"2011","unstructured":"Potente, S., Coppa, K., Williams, A. & Engels, R. Legally brown: using ethnographic methods to understand sun protection attitudes and behaviours among young Australians 'I didn't mean to get burnt\u2014it just happened!'. Health Educ. Res. 26, 39\u201352 (2011).","journal-title":"Health Educ. Res."},{"key":"BFnrclinonc201592_CR96","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/CEJ.0b013e3283354847","volume":"19","author":"R Br\u00e4nstr\u00f6m","year":"2010","unstructured":"Br\u00e4nstr\u00f6m, R. et al. Melanoma risk factors, perceived threat and intentional tanning: an international online survey. Eur. J. Cancer Prev. 19, 216\u2013226 (2010).","journal-title":"Eur. J. Cancer Prev."},{"key":"BFnrclinonc201592_CR97","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1001\/archderm.138.10.1311","volume":"138","author":"JM Knight","year":"2002","unstructured":"Knight, J. M., Kirincich, A. N., Farmer, E. R. & Hood, A. F. Awareness of the risks of tanning lamps does not influence behavior among college students. Arch. Dermatol. 138, 1311\u20131315 (2002).","journal-title":"Arch. Dermatol."},{"key":"BFnrclinonc201592_CR98","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1016\/j.jadohealth.2012.09.021","volume":"52","author":"DM Holman","year":"2013","unstructured":"Holman, D. M. & Watson, M. Correlates of intentional tanning among adolescents in the United States: a systematic review of the literature. J. Adolesc. Health 52, S52\u2013S59 (2013).","journal-title":"J. Adolesc. Health"},{"key":"BFnrclinonc201592_CR99","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/19325037.2013.852997","volume":"45","author":"JW Merten","year":"2014","unstructured":"Merten, J. W., Higgins, S., Rowan, A. & Pragle, A. Sun safety knowledge, attitudes, and behaviors among beachgoing adolescents. Am. J. Health Educ. 45, 37\u201341 (2014).","journal-title":"Am. J. Health Educ."},{"key":"BFnrclinonc201592_CR100","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/ijc.28956","volume":"136","author":"MR Iannacone","year":"2015","unstructured":"Iannacone, M. R., Youlden, D. R., Baade, P. D., Aitken, J. F. & Green, A. C. Melanoma incidence trends and survival in adolescents and young adults in Queensland, Australia. Int. J. Cancer 136, 603\u2013609 (2015).","journal-title":"Int. J. Cancer"},{"key":"BFnrclinonc201592_CR101","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5070\/D366X188MB","volume":"5","author":"BP Hazen","year":"1999","unstructured":"Hazen, B. P., Bhatia, A. C., Zaim, T. & Brodell, R. T. The clinical diagnosis of early malignant melanoma: expansion of the ABCD criteria to improve diagnostic sensitivity. Dermatol. Online J. 5, 3 (1999).","journal-title":"Dermatol. Online J."},{"key":"BFnrclinonc201592_CR102","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1001\/jama.292.22.2771","volume":"292","author":"NR Abbasi","year":"2004","unstructured":"Abbasi, N. R. et al. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA 292, 2771\u20132776 (2004).","journal-title":"JAMA"},{"key":"BFnrclinonc201592_CR103","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/bjd.12003","volume":"168","author":"LJ Titus","year":"2013","unstructured":"Titus, L. J. et al. Recent skin self-examination and doctor visits in relation to melanoma risk and tumour depth. Br. J. Dermatol. 168, 571\u2013576 (2013).","journal-title":"Br. J. Dermatol."},{"key":"BFnrclinonc201592_CR104","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1111\/bjd.12250","volume":"168","author":"V De Giorgi","year":"2013","unstructured":"De Giorgi, V. et al. Skin self-examination and the ABCDE rule in the early diagnosis of melanoma: is the game over? Br. J. Dermatol. 168, 1370\u20131371 (2013).","journal-title":"Br. J. Dermatol."},{"key":"BFnrclinonc201592_CR105","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/j.jaad.2011.04.038","volume":"65","author":"HK Weir","year":"2011","unstructured":"Weir, H. K. et al. Melanoma in adolescents and young adults (ages 15\u201339 years): United States, 1999\u20132006. J. Am. Acad. Dermatol. 65, S38\u2013S49 (2011).","journal-title":"J. Am. Acad. Dermatol."},{"key":"BFnrclinonc201592_CR106","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jaad.2012.12.953","volume":"68","author":"KM Cordoro","year":"2013","unstructured":"Cordoro, K. M., Gupta, D., Frieden, I. J., McCalmont, T. & Kashani-Sabet, M. Pediatric melanoma: results of a large cohort study and proposal for modified ABCD detection criteria for children. J. Am. Acad. Dermatol. 68, 913\u2013925 (2013).","journal-title":"J. Am. Acad. Dermatol."},{"key":"BFnrclinonc201592_CR107","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/PAS.0b013e31826485c0","volume":"37","author":"GV Long","year":"2013","unstructured":"Long, G. V. et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am. J. Surg. Pathol. 37, 61\u201365 (2013).","journal-title":"Am. J. Surg. Pathol."},{"key":"BFnrclinonc201592_CR108","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1479-5876-10-85","volume":"10","author":"PA Ascierto","year":"2012","unstructured":"Ascierto, P. A. et al. The role of BRAF V600 mutation in melanoma. J. Transl. Med. 10, 85 (2012).","journal-title":"J. Transl. Med."},{"key":"BFnrclinonc201592_CR109","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2174\/157489209787002461","volume":"4","author":"KK Wong","year":"2009","unstructured":"Wong, K. K. Recent developments in anti-cancer agents targeting the Ras\/Raf\/ MEK\/ERK pathway. Recent Pat. Anticancer Drug Discov. 4, 28\u201335 (2009).","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"BFnrclinonc201592_CR110","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.bcp.2010.03.019","volume":"80","author":"C Wellbrock","year":"2010","unstructured":"Wellbrock, C. & Hurlstone, A. BRAF as therapeutic target in melanoma. Biochem. Pharmacol. 80, 561\u2013567 (2010).","journal-title":"Biochem. Pharmacol."},{"key":"BFnrclinonc201592_CR111","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1158\/1535-7163.MCT-10-0799","volume":"10","author":"ER Cantwell-Dorris","year":"2011","unstructured":"Cantwell-Dorris, E. R., O'Leary, J. J. & Sheils, O. M. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol. Cancer Ther. 10, 385\u2013394 (2011).","journal-title":"Mol. Cancer Ther."},{"key":"BFnrclinonc201592_CR112","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/978-3-642-54490-3_13","volume":"201","author":"C Garbe","year":"2014","unstructured":"Garbe, C., Abusaif, S. & Eigentler, T. K. Vemurafenib. Recent Results Cancer Res. 201, 215\u2013225 (2014).","journal-title":"Recent Results Cancer Res."},{"key":"BFnrclinonc201592_CR113","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/nrclinonc.2011.69","volume":"8","author":"A Ribas","year":"2011","unstructured":"Ribas, A. & Flaherty, K. T. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat. Rev. Clin. Oncol. 8, 426\u2013433 (2011).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"BFnrclinonc201592_CR114","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/nrd3304","volume":"9","author":"A Flemming","year":"2010","unstructured":"Flemming, A. Cancer: targeting mutant BRAF in metastatic melanoma. Nat. Rev. Drug Discov. 9, 841 (2010).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnrclinonc201592_CR115","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1158\/1541-7786.MCR-07-2001","volume":"6","author":"E Sala","year":"2008","unstructured":"Sala, E. et al. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol. Cancer Res. 6, 751\u2013759 (2008).","journal-title":"Mol. Cancer Res."},{"key":"BFnrclinonc201592_CR116","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/nature09454","volume":"467","author":"G Bollag","year":"2010","unstructured":"Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596\u2013599 (2010).","journal-title":"Nature"},{"key":"BFnrclinonc201592_CR117","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1002011","volume":"63","author":"KT Flaherty","year":"2010","unstructured":"Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 63, 809\u2013819 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201592_CR118","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1038\/onc.2011.424","volume":"31","author":"KJ Basile","year":"2012","unstructured":"Basile, K. J., Abel, E. V. & Aplin, A. E. Adaptive upregulation of FOXD3 and resistance to PLX4032\/4720-induced cell death in mutant B-RAF melanoma cells. Oncogene 31, 2471\u20132479 (2012).","journal-title":"Oncogene"},{"key":"BFnrclinonc201592_CR119","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nature13121","volume":"508","author":"C Sun","year":"2014","unstructured":"Sun, C. et al. Reversible and adaptive resistance to BRAFV600E inhibition in melanoma. Nature 508, 118\u2013122 (2014).","journal-title":"Nature"},{"key":"BFnrclinonc201592_CR120","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1074\/mcp.M113.037424","volume":"13","author":"VW Rebecca","year":"2014","unstructured":"Rebecca, V. W. et al. Evaluating melanoma drug response and therapeutic escape with quantitative proteomics. Mol. Cell Proteomics 13, 1844\u20131854 (2014).","journal-title":"Mol. Cell Proteomics"},{"key":"BFnrclinonc201592_CR121","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1158\/2159-8290.CD-13-1038","volume":"4","author":"O Abdel-Wahab","year":"2014","unstructured":"Abdel-Wahab, O. et al. Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies. Cancer Discov. 4, 538\u2013545 (2014).","journal-title":"Cancer Discov."},{"key":"BFnrclinonc201592_CR122","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/1477-3163.126759","volume":"13","author":"A Jarkowski","year":"2014","unstructured":"Jarkowski, A. & Khushalani, N. I. BRAF and beyond: tailoring strategies for the individual melanoma patient. J. Carcinog. 13, 1 (2014).","journal-title":"J. Carcinog."},{"key":"BFnrclinonc201592_CR123","unstructured":"GlaxoSmithKline Media. Trametinib (Mekinist\u2122) and dabrafenib (Tafinlar\u2122) combination demonstrated overall survival benefit compared to vemurafenib; phase III BRAF V600-mutant metastatic melanoma study stopped early [online] , (2014)."},{"key":"BFnrclinonc201592_CR124","first-page":"273","volume":"28","author":"M Rastrelli","year":"2014","unstructured":"Rastrelli, M. et al. Melanoma m1: diagnosis and therapy. In Vivo 28, 273\u2013285 (2014).","journal-title":"In Vivo"},{"key":"BFnrclinonc201592_CR125","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.gde.2012.01.003","volume":"22","author":"RL Yauch","year":"2012","unstructured":"Yauch, R. L. & Settleman, J. Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis. Curr. Opin. Genet. Dev. 22, 45\u201349 (2012).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"BFnrclinonc201592_CR126","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/B978-0-12-397927-8.00013-0","volume":"65","author":"K Dutton-Regester","year":"2012","unstructured":"Dutton-Regester, K. & Hayward, N. K. Whole genome and exome sequencing of melanoma: a step toward personlized targeted therapy. Adv. Pharmacol. 65, 399\u2013435 (2012).","journal-title":"Adv. Pharmacol."},{"key":"BFnrclinonc201592_CR127","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3109\/09546634.2012.697986","volume":"25","author":"C Perrin","year":"2014","unstructured":"Perrin, C. et al. Metastatic melanoma: results of 'classical' second-line treatment with cytotoxic chemotherapies. J. Dermatolog. Treat. 25, 396\u2013400 (2014).","journal-title":"J. Dermatolog. Treat."},{"key":"BFnrclinonc201592_CR128","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3322\/canjclin.50.4.215","volume":"50","author":"DS Rigel","year":"2000","unstructured":"Rigel, D. S. & Carucci, J. A. Malignant melanoma. Prevention, early detection, and treatment in the 21st century. CA Cancer J. Clin. 50, 215\u2013236 (2000).","journal-title":"CA Cancer J. Clin."},{"key":"BFnrclinonc201592_CR129","first-page":"34","volume":"16","author":"SS Legha","year":"1989","unstructured":"Legha, S. S. Current therapy for malignant melanoma. Semin. Oncol. 16, 34\u201344 (1989).","journal-title":"Semin. Oncol."},{"key":"BFnrclinonc201592_CR130","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1053\/j.seminoncol.2009.07.001","volume":"36","author":"JM Kirkwood","year":"2009","unstructured":"Kirkwood, J. M., Jukic, D. M., Averbook, B. J. & Sender, L. S. Melanoma in pediatric, adolescent, and young adult patients. Semin. Oncol. 36, 419\u2013431 (2009).","journal-title":"Semin. Oncol."},{"key":"BFnrclinonc201592_CR131","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00403-014-1457-7","volume":"306","author":"A Mamalis","year":"2014","unstructured":"Mamalis, A., Garcha, M., Jagdeo, J. Targeting the PD-1 pathway: a promising future for the treatment of melanoma. Arch. Dermatol. Res. 306, 511\u2013519 (2014).","journal-title":"Arch. Dermatol. Res."},{"key":"BFnrclinonc201592_CR132","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201592_CR133","unstructured":"Bristol-Myers Squibb Press Releases. Phase 3 first-line melanoma study of nivolumab, an investigational PD-1 checkpoint inhibitor, demonstrates superior overall survival compared to dacarbazine; Study stopped early [online] , (2014)."},{"key":"BFnrclinonc201592_CR134","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nrd4326","volume":"13","author":"RM Webster","year":"2014","unstructured":"Webster, R. M. & Mentzer, S. E. The malignant melanoma landscape. Nat. Rev. Drug Discov. 13, 491\u2013492 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"issue":"15_suppl","key":"BFnrclinonc201592_CR135","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1200\/jco.2014.32.15_suppl.3005","volume":"32","author":"Richard Kefford","year":"2014","unstructured":"Kefford, R. et al. Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. Presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting (2014).","journal-title":"Journal of Clinical Oncology"},{"key":"BFnrclinonc201592_CR136","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201592_CR137","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1200\/JCO.2014.56.6018","volume":"33","author":"M Maio","year":"2015","unstructured":"Maio, M. et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J. Clin. Oncol. 33, 1191\u20131196 (2015).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201592_CR138","unstructured":"Merck's pivotal KEYNOTE-006 study in first-line treatment for advanced melanoma met co-primary endpoints and will be stopped early. Merck [online] , (2015)."},{"key":"BFnrclinonc201592_CR139","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/intimm\/dxu095","volume":"27","author":"GK Philips","year":"2015","unstructured":"Philips, G. K. & Atkins, M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int. Immunol. 27, 39\u201346 (2015).","journal-title":"Int. Immunol."},{"key":"BFnrclinonc201592_CR140","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.coi.2015.01.006","volume":"33,","author":"DS Shin","year":"2015","unstructured":"Shin, D. S. & Ribas, A. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr. Opin. Immunol. 33, 23\u201335 (2015).","journal-title":"Curr. Opin. Immunol."},{"key":"BFnrclinonc201592_CR141","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s40265-015-0376-z","volume":"75","author":"KK Tsai","year":"2015","unstructured":"Tsai, K. K. & Daud, A. L. The role of anti-PD-1\/PD-L1 agents in melanoma: progress to date. Drugs 75, 563\u2013575 (2015).","journal-title":"Drugs"},{"key":"BFnrclinonc201592_CR142","doi-asserted-by":"publisher","unstructured":"Mahoney, K. M., Freeman, G. J. & McDermott, D. F. The next immune-checkpoint inhibitors: PD-1\/PD-L1 blockade in melanoma. Clin. Ther. http:\/\/dx.doi.org\/10.1016\/j.clinthera.2015.02.018","DOI":"10.1016\/j.clinthera.2015.02.018"},{"key":"BFnrclinonc201592_CR143","unstructured":"Beaupin, L. Are adolescents overlooked in clinical trials? Roswell Park Cancer Institute [online] , (2013)."},{"key":"BFnrclinonc201592_CR144","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.1542\/peds.2014-0122D","volume":"133","author":"E Tai","year":"2014","unstructured":"Tai, E. et al. Understanding and addressing the lack of clinical trial enrollment among adolescents with cancer. Pediatrics 133, S98\u2013S103 (2014).","journal-title":"Pediatrics"},{"key":"BFnrclinonc201592_CR145","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1016\/S1470-2045(14)70113-5","volume":"15","author":"LA Fern","year":"2014","unstructured":"Fern, L. A., Lewandowski, J. A., Coxon, K. M. & Whelan, J., for the National Cancer Research Institute Teenage and Young Adult Clinical Studies Group UK. Available, accessible, aware, appropriate, and acceptable: a strategy to improve participation of teenagers and young adults in cancer trials. Lancet Oncol. 15, e341\u2013e350 (2014).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc201592_CR146","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1200\/JCO.2012.45.4553","volume":"31","author":"JM Unger","year":"2013","unstructured":"Unger, J. M. et al. Patient income level and cancer clinical trial participation. J. Clin. Oncol. 31, 536\u2013542 (2013).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201592_CR147","doi-asserted-by":"publisher","first-page":"dju002","DOI":"10.1093\/jnci\/dju002","volume":"106","author":"JM Unger","year":"2014","unstructured":"Unger, J. M. et al. Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J. Natl Cancer Inst. 106, dju002 (2014).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc201592_CR148","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.2013.53.8009","volume":"32","author":"LM Ellis","year":"2014","unstructured":"Ellis, L. M. et al. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J. Clin. Oncol. 32, 1277\u20131280 (2014).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201592_CR149","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1002\/cncr.23060","volume":"110","author":"ME Burke","year":"2007","unstructured":"Burke, M. E., Albritton, K. & Marina, N. Challenges in the recruitment of adolescents and young adults to cancer clinical trials. Cancer 110, 2385\u20132393 (2007).","journal-title":"Cancer"},{"key":"BFnrclinonc201592_CR150","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/HMR.0b013e31827292fc","volume":"38","author":"PH Song","year":"2013","unstructured":"Song, P. H., Reiter, K. L., Weiner, B. J., Minasian, L. & McAlearney, A. S. The business case for provider participation in clinical trials research: an application to the National Cancer Institute's community clinical oncology program. Health Care Manage. Rev. 38, 284\u2013294 (2013).","journal-title":"Health Care Manage. Rev."},{"key":"BFnrclinonc201592_CR151","unstructured":"Institute of Medicine. Transforming clinical research in the United States: challenges and opportunities: workshop summary. The National Academies Press [online] , (2010)."},{"key":"BFnrclinonc201592_CR152","unstructured":"National Cancer Institute. Clinical trials offer a path to better care for AYAs with cancer [online] , (2011)."},{"key":"BFnrclinonc201592_CR153","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1542\/peds.2014-0122B","volume":"133","author":"E Tai","year":"2014","unstructured":"Tai, E., Beaupin, L. & Bleyer, A. Clinical trial enrollment among adolescents with cancer: supplement overview. Pediatrics 133, S85\u2013S90 (2014).","journal-title":"Pediatrics"},{"key":"BFnrclinonc201592_CR154","doi-asserted-by":"publisher","first-page":"S114","DOI":"10.1542\/peds.2014-0122G","volume":"133","author":"AA Gupta","year":"2014","unstructured":"Gupta, A. A. & Indelicato, D. J. Increasing the number of clinical trials available to adolescents diagnosed with cancer. Pediatrics 133, S114\u2013S118 (2014).","journal-title":"Pediatrics"},{"key":"BFnrclinonc201592_CR155","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s10552-013-0173-5","volume":"24","author":"CP Kaplan","year":"2013","unstructured":"Kaplan, C. P. et al. Clinical trial discussion, referral, and recruitment: physician, patient, and system factors. Cancer Causes Control 24, 979\u2013988 (2013).","journal-title":"Cancer Causes Control"},{"key":"BFnrclinonc201592_CR156","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1200\/JOP.2011.000476","volume":"8","author":"AR Baer","year":"2012","unstructured":"Baer, A. R., Michaels, M., Good, M. J. & Schapira, L. Engaging referring physicians in the clinical trial process. J. Oncol. Pract. 8, e8\u2013e10 (2012).","journal-title":"J. Oncol. Pract."},{"key":"BFnrclinonc201592_CR157","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1089\/jayao.2013.0030","volume":"3","author":"TJ Gribsby","year":"2014","unstructured":"Gribsby, T. J. et al. Attitudes toward cancer clinical trial participation in young adults with a history of cancer and a healthy college student sample: a preliminary investigation. J. Adolesc. Young Adult Oncol. 3, 20\u201327 (2014).","journal-title":"J. Adolesc. Young Adult Oncol."},{"key":"BFnrclinonc201592_CR158","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/ecc.12180","volume":"24","author":"S Manne","year":"2015","unstructured":"Manne, S. et al. Attitudinal barriers to participation in oncology clinical trials: factor analysis and correlates of barriers. Eur. J. Cancer Care (Engl.). 24, 28\u201338 (2015).","journal-title":"Eur. J. Cancer Care (Engl.)."},{"key":"BFnrclinonc201592_CR159","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1177\/0272989X13511704","volume":"34","author":"S Manne","year":"2014","unstructured":"Manne, S. et al. Knowledge, attitudes, and self-efficacy as predictors of preparedness for oncology clinical trials: a mediational model. Med. Decis. Making 34, 454\u2013463 (2014).","journal-title":"Med. Decis. Making"},{"key":"BFnrclinonc201592_CR160","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1080\/10810730.2010.525296","volume":"15","author":"A Langford","year":"2010","unstructured":"Langford, A., Resnicow, K. & An, L. Clinical trial awareness among racial\/ethnic minorities in HINTS 2007: sociodemographic, attitudinal, and knowledge correlates. J. Health Commun. 15, 92\u2013101 (2010).","journal-title":"J. Health Commun."},{"key":"BFnrclinonc201592_CR161","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/cncr.28483","volume":"120","author":"A Langford","year":"2014","unstructured":"Langford, A. et al. Racial\/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute's Community Cancer Centers Program. Cancer 120, 877\u2013884 (2014).","journal-title":"Cancer"},{"key":"BFnrclinonc201592_CR162","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.1200\/JCO.2011.36.2954","volume":"29","author":"HM Parsons","year":"2011","unstructured":"Parsons, H. M., Harlan, L. C., Seibel, N. L., Stevens, J. L. & Keegan, T. H. Clinical trial participation and time to treatment among adolescents and young adults with cancer: does age at diagnosis or insurance make a difference? J. Clin. Oncol. 29, 4045\u20134053 (2011).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201592_CR163","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/jayao.2013.0011","volume":"3","author":"LP Barakat","year":"2014","unstructured":"Barakat, L. P., Schwartz, L. A., Reilly, A., Deatrick, J. A. & Balis, F. A qualitative study of phase III cancer clinical trial enrollment decision-making: perspectives from adolescents, young adults, caregivers, and providers. J. Adolesc. Young Adult Oncol. 3, 3\u201311 (2014).","journal-title":"J. Adolesc. Young Adult Oncol."},{"key":"BFnrclinonc201592_CR164","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1542\/peds.2008-2878","volume":"124","author":"K Read","year":"2009","unstructured":"Read, K. et al. Decision-making by adolescents and parents of children with cancer regarding health research participation. Pediatrics 124, 959\u2013965 (2009).","journal-title":"Pediatrics"},{"key":"BFnrclinonc201592_CR165","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/pbc.24326","volume":"60","author":"VA Miller","year":"2013","unstructured":"Miller, V. A. et al. Adolescent perspectives on phase I cancer research. Pediatr. Blood Cancer 60, 873\u2013878 (2013).","journal-title":"Pediatr. Blood Cancer"},{"key":"BFnrclinonc201592_CR166","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1748-0361.2012.00432.x","volume":"29","author":"D Sprague","year":"2013","unstructured":"Sprague, D., Russo, J., LaVallie, D. L. & Buchwald, D. Barriers to cancer clinical trial participation among American Indian and Alaska Native tribal college students. J. Rural Health 29, 55\u201360 (2013).","journal-title":"J. Rural Health"},{"key":"BFnrclinonc201592_CR167","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1002\/cncr.26634","volume":"118","author":"PH Shaw","year":"2012","unstructured":"Shaw, P. H. et al. Improved clinical trial enrollment in adolescent and young adult (AYA) oncology patients after the establishment of an AYA oncology program uniting pediatric and medical oncology divisions. Cancer 118, 3614\u20133617 (2012).","journal-title":"Cancer"},{"key":"BFnrclinonc201592_CR168","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1634\/theoncologist.2014-0009","volume":"19","author":"SJ Stoneham","year":"2014","unstructured":"Stoneham, S. J. et al. Adolescents and young adults with a \u201crare\u201d cancer: getting past semantics to optimal care for patients with germ cell tumors. Oncologist 19, 689\u2013692 (2014).","journal-title":"Oncologist"},{"key":"BFnrclinonc201592_CR169","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1002\/pbc.24431","volume":"60","author":"DR Freyer","year":"2013","unstructured":"Freyer, D. R., Felgenhauer, J. Perentesis, J. & COG Adolescent and Young Adult Oncology Discipline Committee. Children's Oncology Group's 2013 blueprint for research: adolescent and young adult oncology. Pediatr. Blood Cancer 60, 1055\u20131058 (2013).","journal-title":"Pediatr. Blood Cancer"},{"key":"BFnrclinonc201592_CR170","doi-asserted-by":"crossref","first-page":"146","DOI":"10.14694\/EdBook_AM.2012.32.179","volume":"2012","author":"SS Grubbs","year":"2012","unstructured":"Grubbs, S. S. The new National Cancer Institute National Clinical Trials Network. Am. Soc. Clin. Oncol. Educ. Book 2012, 146\u2013148 (2012).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"BFnrclinonc201592_CR171","unstructured":"Committee on Cancer Clinical Trials and the NCI Cooperative Group Program (eds Nass, S. J., Moses, H. L. & Mendelsohn, J.). A national cancer clinical trials system for the 21st century: reinvigorating the NCI cooperative group program (The National Academies Press, 2010)."},{"key":"BFnrclinonc201592_CR172","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1542\/peds.2014-0122H","volume":"133","author":"J Felgenhauer","year":"2014","unstructured":"Felgenhauer, J. & Hooke, M. C. Regulatory barriers to clinical trial enrollment of adolescent and young adult oncology patients. Pediatrics 133, S119\u2013S122 (2014).","journal-title":"Pediatrics"},{"key":"BFnrclinonc201592_CR173","doi-asserted-by":"publisher","first-page":"71","DOI":"10.14694\/EdBook_AM.2014.34.71","volume":"2014","author":"J Abrams","year":"2014","unstructured":"Abrams, J. et al. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. Am. Soc. Clin. Oncol. Educ. Book 2014, 71\u201376 (2014).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"BFnrclinonc201592_CR174","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1089\/jayao.2013.0031","volume":"3","author":"JR Gorman","year":"2014","unstructured":"Gorman, J. R. et al. A diversified recruitment approach incorporating social media leads to research participation among young adult-aged female cancer survivors. J. Adolesc. Young Adult Oncol. 3, 59\u201365 (2014).","journal-title":"J. Adolesc. Young Adult Oncol."},{"key":"BFnrclinonc201592_CR175","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1089\/jayao.2012.0030","volume":"2","author":"L Fern","year":"2013","unstructured":"Fern, L. & Whelan, J. National Cancer Research Institute Teenage and Young Adult Clinical Studies Group: the United Kingdom approach to research. International perspectives on AYAO, part 4. J. Adolesc. Young Adult Oncol. 2, 161\u2013166 (2013).","journal-title":"J. Adolesc. Young Adult Oncol."},{"key":"BFnrclinonc201592_CR176","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1200\/JOP.2013.001119","volume":"9","author":"AM Denicoff","year":"2013","unstructured":"Denicoff, A. M. et al. The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations. J. Oncol. Pract. 9, 267\u2013276 (2013).","journal-title":"J. Oncol. Pract."},{"key":"BFnrclinonc201592_CR177","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s11912-013-0324-6","volume":"15","author":"CL Epelman","year":"2013","unstructured":"Epelman, C. L. The adolescent and young adult with cancer: state of the art\u2014psychosocial aspects. Curr. Oncol. Rep. 15, 325\u2013331 (2013).","journal-title":"Curr. Oncol. Rep."},{"key":"BFnrclinonc201592_CR178","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3389\/fonc.2013.00075","volume":"3","author":"AW Smith","year":"2013","unstructured":"Smith, A. W. et al. Unmet support service needs and health-related quality of life among adolescents and young adults with cancer: the AYA HOPE study. Front. Oncol. 3, 75 (2013).","journal-title":"Front. Oncol."},{"key":"BFnrclinonc201592_CR179","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/cncr.27713","volume":"119","author":"BJ Zebrack","year":"2013","unstructured":"Zebrack B. J. et al. Psychosocial service use and unmet need among recently diagnosed adolescent and young adult cancer patients. Cancer 119, 201\u2013214 (2013).","journal-title":"Cancer"},{"key":"BFnrclinonc201592_CR180","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3109\/0284186X.2012.745648","volume":"52","author":"AG Veloso","year":"2013","unstructured":"Veloso, A. G. et al. Unmet needs in cancer rehabilitation during the early cancer trajectory\u2014a nationwide patient survey. Acta Oncol. 52, 372\u2013381 (2013).","journal-title":"Acta Oncol."},{"key":"BFnrclinonc201592_CR181","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1002\/pon.3533","volume":"23","author":"BJ Zebrack","year":"2014","unstructured":"Zebrack, B. J. et al. Psychological distress and unsatisfied need for psychosocial support in adolescent and young adult cancer patients during the first year following diagnosis. Psychooncology 23, 1267\u20131275 (2014).","journal-title":"Psychooncology"},{"key":"BFnrclinonc201592_CR182","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/07347332.2013.835018","volume":"31","author":"NM D'Agostino","year":"2013","unstructured":"D'Agostino, N. M. & Edelstein, K. Psychosocial challenges and resource needs of young adult cancer survivors: implications for program development. J. Psychosoc. Oncol. 31, 585\u2013600 (2013).","journal-title":"J. Psychosoc. Oncol."},{"key":"BFnrclinonc201592_CR183","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1007\/s11136-014-0682-z","volume":"23","author":"CL Park","year":"2014","unstructured":"Park, C. L., Wortmann, J. H., Hale, A. E., Cho, D. & Blank, T. O. Assessing quality of life in young adult cancer survivors: development of the Survivorship-Related Quality of Life scale. Qual. Life Res. 23, 2213\u20132224 (2014).","journal-title":"Qual. Life Res."},{"key":"BFnrclinonc201592_CR184","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s12529-012-9227-4","volume":"20","author":"C Rabin","year":"2013","unstructured":"Rabin, C., Simpson, N., Morrow, K. & Pinto, B. Intervention format and delivery preferences among young adult cancer survivors. Int. J. Behav. Med. 20, 304\u2013310 (2013).","journal-title":"Int. J. Behav. Med."},{"key":"BFnrclinonc201592_CR185","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11764-013-0271-0","volume":"7","author":"PC Nathan","year":"2013","unstructured":"Nathan, P. C. et al. Family physician preferences and knowledge gaps regarding the care of adolescent and young adult survivors of childhood cancer. J. Cancer Surviv. 7, 275\u2013282 (2013).","journal-title":"J. Cancer Surviv."},{"key":"BFnrclinonc201592_CR186","doi-asserted-by":"publisher","first-page":"E17","DOI":"10.1097\/NCC.0b013e318278d4fc","volume":"36","author":"MA Hauken","year":"2013","unstructured":"Hauken, M. A., Larsen, T. M. & Holsen, I. Meeting reality: young adult cancer survivors' experiences of reentering everyday life after cancer treatment. Cancer Nurs. 36, E17\u2013E26 (2013).","journal-title":"Cancer Nurs."},{"key":"BFnrclinonc201592_CR187","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/pbc.24490","volume":"60","author":"L Wiener","year":"2013","unstructured":"Wiener, L., Zadeh, S., Wexler, L. H. & Pao, M. When silence is not golden: engaging adolescents and young adults in discussions around end-of-life care choices. Pediatr. Blood Cancer 60, 715\u2013718 (2013).","journal-title":"Pediatr. Blood Cancer"},{"key":"BFnrclinonc201592_CR188","doi-asserted-by":"publisher","unstructured":"Zadeh, S., Pao, M. & Wiener, L. Opening end-of-life discussions: how to introduce Voicing My CHOiCES\u2122, an advance care planning guide for adolescents and young adults. Palliat. Support. Care http:\/\/dx.doi.org\/10.1017\/S1478951514000054 (2014).","DOI":"10.1017\/S1478951514000054"},{"key":"BFnrclinonc201592_CR189","doi-asserted-by":"crossref","unstructured":"Nass, S. J. & Patlak, M. (eds) Identifying and addressing the needs of adolescents and young adults with cancer: workshop summary (2013). The National Academies Press [online] , (2013).","DOI":"10.17226\/18547"},{"key":"BFnrclinonc201592_CR190","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1542\/peds.2004-1449","volume":"116","author":"ST Callahan","year":"2005","unstructured":"Callahan, S. T. & Cooper, W. O. Uninsurance and health care access among young adults in the United States. Pediatrics 116, 88\u201395 (2005).","journal-title":"Pediatrics"},{"key":"BFnrclinonc201592_CR191","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1002\/cncr.22102","volume":"107","author":"A Bleyer","year":"2006","unstructured":"Bleyer, A., Budd, T. & Montello, M. Adolescents and young adults with cancer: the scope of the problem and criticality of clinical trials. Cancer 107, 1645\u20131655 (2006).","journal-title":"Cancer"},{"key":"BFnrclinonc201592_CR192","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s11764-012-0225-y","volume":"6","author":"ER Park","year":"2012","unstructured":"Park, E. R. et al. Childood Cancer Survivor Study participants' perceptions and knowledge of health insurance coverage: implications for the Affordable Care Act. J. Cancer Surviv. 6, 251\u2013259 (2012).","journal-title":"J. Cancer Surviv."},{"key":"BFnrclinonc201592_CR193","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s10900-010-9328-4","volume":"36","author":"LG Wich","year":"2011","unstructured":"Wich, L. G. et al. Impact of socioeconomic status and sociodemographic factors on melanoma presentation among ethnic minorities. J. Community Health 36, 461\u2013468 (2011).","journal-title":"J. Community Health"},{"key":"BFnrclinonc201592_CR194","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jamasurg.2013.1680","volume":"148","author":"EC Smith","year":"2013","unstructured":"Smith, E. C., Ziogas, A. & Anton-Culver, H. Delay in surgical treatment and survival after breast cancer diagnosis in young women by race\/ethnicity. JAMA Surg. 148, 516\u2013523 (2013).","journal-title":"JAMA Surg."},{"key":"BFnrclinonc201592_CR195","doi-asserted-by":"publisher","first-page":"6179","DOI":"10.1002\/cncr.27684","volume":"118","author":"EC Smith","year":"2012","unstructured":"Smith, E. C., Ziogas, A. & Anton-Culver, H. Association between insurance and socioeconomic status and risk of advanced stage Hodgkin lymphoma in adolescents and young adults. Cancer 118, 6179\u20136187 (2012).","journal-title":"Cancer"},{"key":"BFnrclinonc201592_CR196","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/cam4.84","volume":"2","author":"X Niu","year":"2013","unstructured":"Niu, X., Roche, L. M., Pawlish, K. S. & Henry, K. A. Cancer survival disparities by health insurance status. Cancer Med. 2, 403\u2013411 (2013).","journal-title":"Cancer Med."},{"key":"BFnrclinonc201592_CR197","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1200\/JCO.2012.47.3173","volume":"31","author":"AW Smith","year":"2013","unstructured":"Smith, A. W. et al. Health-related quality of life of adolescent and young adult patients with cancer in the United States: the Adolescent and Young Adult Health Outcomes and Patient Experience study. J. Clin. Oncol. 31, 2136\u20132145 (2013).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201592_CR198","doi-asserted-by":"publisher","first-page":"4810","DOI":"10.1200\/JCO.2009.23.4278","volume":"28","author":"DR Freyer","year":"2010","unstructured":"Freyer, D. R. Transition of care for young adult survivors of childhood and adolescent cancer: rationale and approaches. J. Clin. Oncol. 28, 4810\u20134818 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201592_CR199","doi-asserted-by":"publisher","first-page":"5964","DOI":"10.1002\/cncr.27537","volume":"118","author":"AC Kirchhoff","year":"2012","unstructured":"Kirchhoff, A. C., Lyles, C. R., Fluchel, M., Wright, J. & Leisenring, W. Limitations in health care access and utilization among long-term survivors of adolescent and young adult cancer. Cancer 118, 5964\u20135972 (2012).","journal-title":"Cancer"},{"key":"BFnrclinonc201592_CR200","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1200\/JCO.2013.54.2555","volume":"32","author":"AA Aizer","year":"2014","unstructured":"Aizer, A. A. et al. Cancer-specific outcomes among young adults without health insurance. J. Clin. Oncol. 32, 2025\u20132030 (2014).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201592_CR201","unstructured":"US Department of Health & Human Services. Young adult coverage [online] , (2014)."},{"key":"BFnrclinonc201592_CR202","unstructured":"US Department of Health & Human Services. Preventive services covered under the Affordable Care Act [online] , (2012)."},{"key":"BFnrclinonc201592_CR203","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1377\/hlthaff.2013.1425","volume":"33","author":"GP Guy","year":"2014","unstructured":"Guy, G. P. et al. Estimating the health and economic burden of cancer among those diagnosed as adolescents and young adults. Health Aff. (Millwood) 33, 1024\u20131031 (2014).","journal-title":"Health Aff. (Millwood)"},{"key":"BFnrclinonc201592_CR204","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1037\/0003-066X.55.5.469","volume":"55","author":"JJ Arnett","year":"2000","unstructured":"Arnett, J. J. Emerging adulthood. A theory of development from the late teens through the twenties. Am. Psychol. 55, 469\u2013480 (2000).","journal-title":"Am. Psychol."},{"key":"BFnrclinonc201592_CR205","unstructured":"The National Collaborating Centre for Cancer. Improving outcomes in children and young people with cancer. The National Institute for Health and Clinical Excellence [online] , (2005)."},{"key":"BFnrclinonc201592_CR206","doi-asserted-by":"publisher","first-page":"4862","DOI":"10.1200\/JCO.2010.30.5417","volume":"28","author":"B Zebrack","year":"2010","unstructured":"Zebrack, B., Mathews-Bradshaw, B., Siegel, S. & LIVESTRONG Young Adult Alliance. Quality cancer care for adolescents and young adults: a position statement. J. Clin. Oncol. 28, 4862\u20134867 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201592_CR207","doi-asserted-by":"publisher","first-page":"4858","DOI":"10.1200\/JCO.2010.30.5508","volume":"28","author":"B Hayes-Lattin","year":"2010","unstructured":"Hayes-Lattin, B., Mathews-Bradshaw, B. & Siegel, S. Adolescent and young adult oncology training for health professionals: a position statement. J. Clin. Oncol. 28, 4858\u20134861 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201592_CR208","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3322\/caac.21219","volume":"64","author":"E Ward","year":"2014","unstructured":"Ward, E., DeSantis, C., Robbins, A., Kohler, B. & Jemal, A. Childhood and adolescent cancer statistics, 2014. CA Cancer J. Clin. 64, 83\u2013103 (2014).","journal-title":"CA Cancer J. Clin."},{"key":"BFnrclinonc201592_CR209","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/pbc.24252","volume":"60","author":"JM Mulcahy Levy","year":"2013","unstructured":"Mulcahy Levy, J. M. et al. Late effects of total body irradiation and hematopoietic stem cell transplant in children under 3 years of age. Pediatr. Blood Cancer 60, 700\u2013704 (2013).","journal-title":"Pediatr. Blood Cancer"},{"key":"BFnrclinonc201592_CR210","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1080\/09297049.2012.669470","volume":"19","author":"KR Wolfe","year":"2013","unstructured":"Wolfe, K. R. et al. Executive functions and social skills in survivors of pediatric brain tumor. Child Neuropsycol. 19, 370\u2013384 (2013).","journal-title":"Child Neuropsycol."},{"key":"BFnrclinonc201592_CR211","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1188\/13.ONF.254-262","volume":"40","author":"W McClellan","year":"2013","unstructured":"McClellan, W. et al. Understanding the functional late effects and informational needs of adult survivors of childhood cancer. Oncol. Nurs. Forum 40, 254\u2013262 (2013).","journal-title":"Oncol. Nurs. Forum"},{"key":"BFnrclinonc201592_CR212","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/ddrr.33","volume":"14","author":"RW Butler","year":"2008","unstructured":"Butler, R. W. et al. Interventions to improve neuropsychological functioning in childhood cancer survivors. Dev. Disabil. Res. Rev. 14, 251\u2013258 (2008).","journal-title":"Dev. Disabil. Res. Rev."},{"key":"BFnrclinonc201592_CR213","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/MRR.0000000000000071","volume":"37","author":"DD Lange","year":"2014","unstructured":"Lange, D. D., Wong, A. W., Strauser, D. R. & Wagner, S. Vocational identity, positive affect, and career thoughts in a group of young adult central nervous system cancer survivors. Int. J. Rehabil. Res. 37, 297\u2013301 (2014).","journal-title":"Int. J. Rehabil. Res."},{"key":"BFnrclinonc201592_CR214","doi-asserted-by":"publisher","first-page":"754","DOI":"10.2340\/16501977-1840","volume":"46","author":"F Khan","year":"2014","unstructured":"Khan, F., Amatya, B., Drummond, K. & Galea, M. Effectiveness of integrated multidisciplinary rehabilitation in primary brain cancer survivors in an Australian community cohort: a controlled clinical trial. J. Rehabil. Med. 46, 754\u2013760 (2014).","journal-title":"J. Rehabil. Med."},{"key":"BFnrclinonc201592_CR215","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/pon.3387","volume":"23","author":"F Schulte","year":"2014","unstructured":"Schulte, F., Vannatta, K. & Barrera, M. Social problem solving and social performance after a group social skills intervention for childhood brain tumor survivors. Psychooncology 23, 183\u2013189 (2014).","journal-title":"Psychooncology"},{"key":"BFnrclinonc201592_CR216","doi-asserted-by":"publisher","first-page":"698528","DOI":"10.1155\/2013\/698528","volume":"2013","author":"SP Rodgers","year":"2013","unstructured":"Rodgers, S. P., Trevino, M., Zawaski, J. A., Gaber, M. W. & Leasure, J. L. Neurogenesis, exercise, and cognitive late effects of pediatric radiotherapy. Neural Plast. 2013, 698528 (2013).","journal-title":"Neural Plast."},{"key":"BFnrclinonc201592_CR217","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.2217\/fon.13.107","volume":"9","author":"RL Mulder","year":"2013","unstructured":"Mulder, R. L., Hudson, M. M., Skinner, R. & Kremer, L. C. Health problems in survivors of childhood cancer: the need for international collaboration in long-term follow-up care. Future Oncol. 9, 1667\u20131670 (2013).","journal-title":"Future Oncol."},{"key":"BFnrclinonc201592_CR218","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3346\/jkms.2013.28.5.755","volume":"28","author":"JW Han","year":"2013","unstructured":"Han, J. W. et al. Increasing and worsening late effects in childhood cancer survivors during follow-up. J. Korean Med. Sci. 28, 755\u2013762 (2013).","journal-title":"J. Korean Med. Sci."},{"key":"BFnrclinonc201592_CR219","unstructured":"CureSearch Children's Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers [online] , (2008)."},{"key":"BFnrclinonc201592_CR220","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S1470-2045(14)70265-7","volume":"15","author":"S Essig","year":"2014","unstructured":"Essig, S. et al. Risk of late effects of treatment in children newly diagnosed with standard-risk acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 15, 841\u2013851 (2014).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc201592_CR221","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1002\/pon.3217","volume":"22","author":"M Kwak","year":"2013","unstructured":"Kwak, M. et al. Prevalence and predictors of post-traumatic stress symptoms in adolescent and young adult cancer survivors: a 1-year follow-up study. Psychooncology 22, 1798\u20131806 (2013).","journal-title":"Psychooncology"},{"key":"BFnrclinonc201592_CR222","volume-title":"BBC News","author":"J Gallagher","year":"2015","unstructured":"Gallagher, J. DNA project 'to make UK world genetic research leader'. BBC News [online] , (2015)."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2015.92.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2015.92","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2015.92.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:29:25Z","timestamp":1684466965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2015.92"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,26]]},"references-count":222,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["BFnrclinonc201592"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2015.92","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,26]]},"assertion":[{"value":"26 May 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}